Seoul National University, South Korea
Localized renal cell carcinoma patients had worse prognosis with than without capsular invasion
Published in Medicine and Law Weekly, July 7th, 2006
"[The study's aim was] to analyze the prognostic value of capsular invasion without perinephric fat infiltration in patients with localized RCC Stage pT1-pT2N0M0. A total of 288 patients with RCC (conventional type) confined to the kidney (pT1-pT2N0M0) who underwent radical nephrectomy from January 1993 to November 2004 at our institution were included in our study," scientists in South Korea reported.
"The disease of all patients was staged according to the 2002 TNM classification system," explained I.G. Jeong and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- Accu-Break Pharmaceuticals
Accu-Break, Strides Arcolab enter joint venture to develop generic pharmaceuticals - Alnylam Pharmaceuticals
Alnylam issued U.S. patent broadly covering RNAi therapeutics - Awards
Humana wins Stevie Award for best new product - Baylor College of Medicine, U.S.
Ethics for clinical trials enrollment for women of childbearing potential emphasized - Biophan Technologies
Biophan is issued U.S. patents related to cardiac pacing - Bradmer Pharmaceuticals
Bradmer extends patent portfolio with allowance letter from European Patent Office - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
